Latest news
{{'2026-02-25T13:00:00Z' | dateFormatFilter}}
Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes
{{'2026-02-24T13:00:00Z' | dateFormatFilter}}
Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access
{{'2026-02-24T08:39:34Z' | dateFormatFilter}}
Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China
Investors
Share price
{{priceData.date}} {{priceData.time}}
{{priceData.currentPrice}}
{{priceData.currency}}
Go to stock watch
{{priceData.change}} {{priceData.currency}}
